HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

被引：0

作者：

Mateos, Maria-Victoria

Oriol, Albert

Larocca, Alessandra

Blade, Joan

Cavo, Michele

Rodriguez Otero, Paula

Leleu, Xavier

Hiemenz, John W.

Hassoun, Hani

Touzeau, Cyrille

Alegre, Adrian

Paner, Agne

Maisel, Christopher

Mazumder, Amitabha

Raptis, Anastasios

Harmenberg, Johan

Zavisic, Stojan

Thuresson, Sara

Ohman, Oskar

Richardson, Paul G.

机构：

[1] Univ Hosp Salamanca, Canc Res Ctr IBMCC USAL CSIC, IBSAL, Salamanca, Spain

[2] Hosp Badalona Germans Trias & Pujol, Inst Invest Leucemia Josep Carreras, Badalona, Spain

[3] Hosp Badalona Germans Trias & Pujol, Inst Catela Oncol, Badalona, Spain

[4] AOU Citta Salute & Sci Torino SC, Ematol u, Torin, Italy

[5] Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain

[6] St Orsola Marcello Malpighi Hosp, Bologna, Italy

[7] Clin Univ Navarra Pamploma, Navarra, Spain

[8] CHU Poitiers, Poitiers, France

[9] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA

[10] Mem Sloan Kettering Canc, Myeloma Serv, Dept Med, New York, NY USA

[11] Ctr Hosp Univ, Nantes, France

[12] Hosp Univ La Princesa, Madrid, Spain

[13] Assoc Med Onc, Bolingbrook, IL USA

[14] Baylor Scott & White Charles A Sammons Canc Ctr, Dallas, TX USA

[15] Oncol Inst Hope & Innovat, Glendale, CA USA

[16] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[17] Oncopeptides AB, Stockholm, Sweden

[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20570

引用

页数：2

共 50 条

[41] OCEAN (OP-103): PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA TREATED WITH MELFLUFEN PLUS DEXAMETHASONE OR POMALIDOMIDE PLUS DEXAMETHASONE - A RESOURCE UTILIZATION ANALYSIS OF ADVERSE EVENTS LEADING TO HOSPITALIZATIONS
Schjesvold, Hellem F.
Ludwig, H.
Delimpasi, S.
Robak, P.
Mateos, M., V
Sandberg, A.
Obermueller, J.
Norin, S.
Richardson, P. G.
Sonneveld, P.
VALUE IN HEALTH, 2023, 26 (12) : S64 - S64
[42] OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators
Schjesvold, Fredrik
Ludwig, Heinz
Mateos, Maria-Victoria
Abdulhaq, Haifaa
Norin, Stefan
Thuresson, Marcus
Bakker, Nicolaas A.
Richardson, Paul G.
Sonneveld, Pieter
BLOOD, 2022, 140 : 12607 - 12609
[43] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Richardson, Paul
Sandhu, Irwindeep
Oriol, Albert
Raab, Marc S.
White, Darrell
LeBlanc, Richard
Perrot, Aurore
Ocio, Enrique
Raje, Noopur
Hansen, Charlotte Toftmann
Zhou, Zehua
Civardi, Tiziana
Ghiddi, Alessandro
Katz, Jessica
Peluso, Teresa
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
[44] Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
van de Donk, Niels
White, Darrell
Lipe, Brea
Khan, Abdullah
Niesvizky, Ruben
Oriol, Albert
Mesa, Mercedes Gironella
Anwer, Faiz
Bhutani, Manisha
McClune, Brian
Singhal, Seema
Cheng, Yiming
Hamada, Izumi
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S214 - S215
[45] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Sandhu, I
Oriol, A.
White, D.
LeBlanc, R.
Perrot, A.
Ocio, E. M.
Raje, N.
Hansen, C. Toftmann
Zhou, Z.
Civardi, T.
Katz, J.
Peluso, T.
Dimopoulos, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
[46] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
Oriol, Albert
Sandhu, Irwindeep
Raab, Marc
White, Darrell
LeBlanc, Richard
Raje, Noopur
Ocio, Enrique
Perrot, Aurore
Facon, Thierry
Rodriguez, Cesar
Waesch, Ralph
Amatangelo, Michael
Zhou, Zehua
Wang, Yue
Civardi, Tiziana
Koo, Philip
Maciag, Paulo
Zhu, Daniel
Katz, Jessica
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
[47] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
Richardson, Paul G.
Sandhu, Irwindeep
Hofmeister, Craig C.
Orlowski, Robert Z.
White, Darrell
Belotti, Angelo
Hansen, Charlotte Toftmann
Raje, Noopur S.
Chow, Tracy T.
Zhou, Zehua
Civardi, Tiziana
Koo, Phillip
Zhu, Yue
Katz, Jessica
Oriol, Albert
BLOOD, 2023, 142
[48] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
Raab, Marc S.
Oriol, Albert
Sandhu, Irwindeep
White, Darrell
Leblanc, Richard
Raje, Noopur
Ocio, Enrique M.
Perrot, Aurore
Facon, Thierry
Rodriguez, Cesar
Waesch, Ralph
Amatangelo, Michael
Zhou, Zehua
Wang, Yue
Civardi, Tiziana
Koo, Phillip
Maciag, Paulo
Zhu, Daniell
Katz, Jessica
Richardson, Paul G.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
[49] Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
Sonneveld, Pieter
Terpos, Evangelos
Dimopoulos, Meletios A.
Ukropec, Jon
Smith, Elena
Houkes, Nienke
Schecter, Jordan Mark
Kastritis, Efstathios
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[50] Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial
Costa, Luciano
Popat, Rakesh
Siegel, David
Schjesvold, Fredrik
Usmani, Saad
Bahlis, Nizar J.
Oriol, Albert
Chu, Michael
Ali, Syed Abbas
Ramasamy, Karthik
Hartley-Brown, Monique
Martinez-Lopez, Joaquin
Gaudy, Allison
Kurtova, Antonina
Zhang, Wen
Sarmiento, Rafael
Dietrich, August
Katz, Jessica
Pourdehnad, Michael
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S19 - S19

← 1 2 3 4 5 →